Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

Pfizer

Status: Completed

Conditions: Spondylitis, Ankylosing

Treatments: Drug: Enbrel

Study type: Observational

Funder types: Industry

Identifiers

NCT01188655

0881X1-4456

B1801095

Details and patient eligibility

About

This observational study will be a documentation of the prescribing and administration practices of Enbrel® and their impact on ankylosing spondylitis patients outcome in a real life setting.

Full description

The study population will be described using standard descriptive statistics for demographic, clinical, medical, characteristics, as well as for standard health-related quality of life and functional disability questionnaires .

Enrollment: 89 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Proven diagnosis of Ankylosing Spondylitisin accordance with local guidelines
• Patients treated as an outpatient

Exclusion criteria

• Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®.
• Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localised infections.
• Patients with sepsis or risk of sepsis should not be treated.

Trial design

89 participants in 1 patient group

Treatment Group Enbrel

Treatment:

Drug: Enbrel